Premium
Results of a conservative treatment combining induction (neoadjuvant) and consolidation chemotherapy, hormonotherapy, and external and interstitial irradiation in 98 patients with locally advanced breast cancer (IIIA‐IIIB)
Author(s) -
Jacquillat Cl.,
Baillet F.,
Weil M.,
Auclerc G.,
Housset M.,
Auclerc Mf.,
Sellami M.,
Jindani A.,
Thill L.,
Soubrane CL.,
Khayat D.
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19880515)61:10<1977::aid-cncr2820611008>3.0.co;2-n
Subject(s) - medicine , chemotherapy , breast cancer , radiation therapy , induction chemotherapy , oncology , stage (stratigraphy) , surgery , cancer , paleontology , biology
Ninety‐eight patients with locally advanced breast cancer (Stage IIIA‐IIIB) were entered into a pilot study combining intensive induction (neoadjuvant) chemotherapy (VTMFAP) with or without hormonochemotherapy, external and interstitial radiotherapy, and consolidation chemotherapy with or without hormonochemotherapy. Tumor regression over 50% was observed in 91% patients after chemotherapy, and complete clinical remission occurred in 100% patients after irradiation. The rate of local relapse is 13%. The 3‐year disease‐free survival is 62% and 3‐year global survival is 77%. Initial chemotherapeutic tumor regression > 75% is the main predictive factor for disease‐free survival.